Why Undeclared Pharmaceutical Screening Matters for Deer Placenta Supplements

Undeclared pharmaceutical substances are pharmacologically active compounds found in a health supplement but not disclosed on its label.

A supplement label identifies the ingredients that a product is intended to contain. However, reading the label alone cannot independently confirm whether the finished product contains undeclared medicines, prohibited substances or related pharmaceutical compounds.

As part of its quality-control program, EINNALAB commissions independent SGS laboratory testing of finished EINNALAB Deer Placenta softgels for selected undeclared pharmaceutical substances and other quality parameters.

The resulting laboratory report provides information about:

• the submitted finished-product sample;
• the batch associated with the sample;
• the substances included in the test;
• the analytical methods used;
• the reported findings.

Testing does not prove that every possible substance is absent. Results remain specific to the tested sample, selected analytes, analytical methods and applicable detection or reporting limits.

Why This Testing Matters for Deer Placenta Supplements

A deer placenta supplement is an animal-derived health supplement. Some formulations, including EINNALAB Deer Placenta, also combine multiple oils, extracts and nutritional ingredients within one finished softgel.

Consumers can read the ingredient list to understand what the product declares. They cannot determine from the packaging alone whether an undeclared pharmaceutical substance is present.

Finished-product screening provides analytical information that cannot be obtained from label review or supplier documentation alone.

This does not mean deer placenta supplements should automatically be presumed to contain undeclared pharmaceutical substances. Testing provides an additional layer of evidence about the finished product after its ingredients have been combined and encapsulated.

For consumers evaluating a deer placenta supplement, relevant questions include:

• Was the finished softgel tested, rather than only the raw ingredients?
• Does the report identify the tested product and batch?
• Which pharmaceutical substances or groups were examined?
• Which independent laboratory performed the analysis?
• What findings were reported?
• What limitations apply to those findings?

Finished-product screening should operate alongside supplier qualification, manufacturing controls and raw-material checks. These controls are explained further in EINNALAB’s guide to how deer placenta supplements are manufactured and tested.

Why Undeclared Pharmaceutical Exposure Can Be Concerning

The significance of a detected pharmaceutical substance depends on factors including:

• its chemical identity;
• the concentration detected;
• frequency and duration of exposure;
• whether more than one active substance is present;
• the consumer’s age and health status;
• prescription medicines or other supplements being used.

Undeclared exposure is especially concerning because the consumer and healthcare professional may not know that the substance is present.

Potential concerns may include:

• unexpected pharmacological effects;
• interactions with prescription medicines;
• effects on heart rate or blood pressure;
• excessive stimulation;
• drowsiness or impaired alertness;
• contraindications for certain medical conditions;
• complications relating to surgery;
• concerns during pregnancy or breastfeeding;
• anti-doping consequences for competitive athletes.

The concern is not limited to a substance being present at a “high level.” The identity, concentration and circumstances of exposure all affect how a finding should be interpreted. A pharmacologically active compound may be unsuitable for a particular consumer even at an amount that might not affect another person in the same way.

What Does Undeclared Pharmaceutical Screening Examine?

There is no single laboratory panel that can identify every pharmaceutical substance that could theoretically be present.

A screening panel examines a defined list of substances selected according to factors such as:

• the product category;
• product presentation and intended use;
• historical adulteration patterns;
• regulatory alerts;
• emerging pharmaceutical analogues;
• available analytical methods;
• the specific purpose of the test.

Singapore’s Health Sciences Authority states that traditional medicines and health supplements may be screened for Western drug adulterants according to their different product indications and associated pharmacological effects. This illustrates why a screening panel should be risk-based rather than treated as a universal test for every health supplement.

Depending on its scope, a screening panel may examine selected:

• sexual-enhancement medicines and related analogues;
• weight-loss drugs and stimulants;
• corticosteroids;
• painkillers and anti-inflammatory medicines;
• sedatives and other central nervous system medicines;
• antihistamines;
• antibiotics and antimicrobials;
• anabolic or steroid-related compounds;
• other specified pharmaceutical substances.

Different categories create different concerns when present without declaration:

• Undeclared stimulants may affect heart rate, blood pressure or the nervous system.
• Undeclared sedatives may cause drowsiness or impaired alertness.
• Undeclared corticosteroids may create risks from repeated or uncontrolled exposure.
• Undeclared pain-relief medicines may interact with other medicines or be unsuitable for some consumers.
• Undeclared sexual-performance medicines may cause clinically significant interactions with certain cardiovascular medicines.

The exact substances examined must always be confirmed from the applicable laboratory report. Undeclared-pharmaceutical screening also answers a different analytical question from targeted hormone testing. Each test must be interpreted according to its own analytes, methods and reporting limits.

How SGS Examines the Submitted Finished Product

EINNALAB commissioned an SGS laboratory to examine a submitted finished-product sample for selected undeclared pharmaceutical substances.

The applicable SGS report should be interpreted according to:

• the product and sample identified;
• the batch or lot number;
• the substances included in the testing scope;
• the analytical methods stated;
• the applicable detection or reporting criteria;
• the findings reported for that sample.

Different pharmaceutical substances may require different analytical techniques. The SGS report may therefore identify more than one test method.

The detailed mechanics of each instrument are not the main issue for consumers. The more important questions are:

• Was the completed softgel tested?
• Were the substances examined clearly identified?
• Was the sample connected to a specific product batch?
• Were the findings issued by an independent laboratory?
• Can the report be matched to the product currently being supplied?

Why Reading the Supplement Label Is Not Enough

A supplement label and a laboratory report serve different purposes.

A supplement label can tell consumers:

• which ingredients are declared;
• the declared amounts;
• serving size;
• directions for use;
• warnings;
• allergen information;
• responsible company details;
• batch and expiry information.

A laboratory report can provide information about:

• the actual sample submitted;
• the batch associated with the sample;
• the substances included in the test;
• the analytical methods used;
• applicable reporting criteria;
• findings for the tested sample.

A product label is a declaration of intended composition. A laboratory report provides analytical findings relating to a specific submitted sample.

This distinction matters because packaging alone cannot independently verify whether undeclared pharmaceutical substances were detected or not detected.

Laboratory reports should be reviewed together with manufacturing information, ingredient transparency and product traceability. These factors are covered in EINNALAB’s deer placenta supplement quality guide.

Laboratory testing does not replace:

• accurate product labelling;
• responsible manufacturing;
• supplier qualification;
• ingredient identity controls;
• batch traceability;
• appropriate storage and handling.

It should operate alongside these controls.

How EINNALAB Uses Finished-Product Testing

As part of its quality-control program, EINNALAB commissions independent finished-product testing for selected chemical and contaminant parameters.

For undeclared pharmaceutical screening, the corresponding SGS laboratory documentation identifies the tested product sample, analytical scope and reported findings.

This approach is intended to provide consumers with information that cannot be obtained from the supplement label alone.

EINNALAB’s testing and transparency framework should include:

• testing of the completed softgel;
• identifiable batch information;
• clearly defined analytical parameters;
• independent laboratory documentation;
• accurate interpretation of non-detected findings;
• access to relevant consumer-facing test information;
• appropriate protection of confidential supplier and manufacturing details.

A publicly accessible laboratory report may be redacted to protect confidential factory, supplier and commercial information. However, redaction should not remove the details needed to understand:

• which product was tested;
• which batch was represented;
• which laboratory conducted the analysis;
• what analytical scope was included;
• what findings were reported.

EINNALAB should only state that every batch receives the same pharmaceutical-screening panel when every released batch is supported by corresponding documentation.

Until that condition is verified, the safer statement is:

As part of its quality-control program, EINNALAB commissions independent batch-specific finished-product testing for selected chemical and contaminant parameters.

What Does “Not Detected” Mean?

A non-detected result generally means that the laboratory did not obtain analytical evidence meeting its defined detection or identification criteria for the specified substance in the sample tested.

It does not necessarily mean that the concentration is mathematically zero.

The International Union of Pure and Applied Chemistry defines a limit of detection in relation to the smallest measurement that can be detected with reasonable certainty under a particular analytical procedure. Detection capability is therefore specific to the test method and conditions used.

A careful interpretation is:

The specified substance was not detected at or above the applicable method threshold in the submitted sample.

A non-detected result does not prove that:

• every possible pharmaceutical substance was examined;
• a substance could not be present below the method’s detection capability;
• every capsule in the production batch is identical;
• a different production batch has the same result;
• the product has been proven completely safe;
• the declared ingredients are clinically effective;
• SGS or a regulatory authority has approved the product.

Testing is valuable, but its meaning must remain connected to the scope and limitations of the laboratory report.

Why Batch-Specific Reports Matter

A laboratory report ordinarily applies to the product sample and batch identified in the document.

A report for an earlier batch does not automatically establish that a later batch underwent the same test or produced the same findings.

A meaningful laboratory record should identify, where applicable:

• product name;
• dosage form;
• batch or lot number;
• sample description;
• date of testing;
• testing laboratory;
• analytical method;
• substances examined;
• applicable reporting criteria;
• reported findings.

Batch-specific documentation strengthens transparency because it allows consumers to determine whether the report relates to the product currently being supplied.

However, pharmaceutical screening remains only one part of a wider quality-control program. Separate controls or tests may be required for:

• ingredient identity;
• heavy metals;
• microbiological quality;
• residual solvents;
• oxidation;
• stability;
• declared ingredient quantities;
• packaging integrity.

Key Takeaways

• Undeclared pharmaceutical substances are pharmacologically active compounds that are not properly disclosed on a supplement label.
• Reading a deer placenta supplement label cannot independently verify whether undeclared pharmaceutical substances are present.
• Finished-product screening provides analytical information about the submitted product sample.
• EINNALAB commissions SGS laboratory testing for selected undeclared pharmaceutical substances and other quality parameters.
• The exact substances, methods and findings must be taken from the applicable SGS report.
• A non-detected result applies only to the identified sample, analytes, methods and reporting limits.
• Laboratory testing does not constitute SGS certification, regulatory approval, product endorsement or a guarantee of safety.
• Batch-specific documentation provides more meaningful transparency than a general or undated “laboratory tested” statement.

Conclusion

SGS laboratory documentation can show which finished-product sample was tested, which substances were included in the analytical scope and what findings were reported.

Every result must remain connected to:

• the identified batch;
• submitted sample;
• selected analytes;
• analytical methods;
• applicable reporting limits.

Independent laboratory testing reduces uncertainty and provides additional product-specific evidence. It does not replace responsible manufacturing, accurate labelling or supplier controls, and it does not constitute regulatory approval, laboratory endorsement or a guarantee of product safety.

Authoritative Sources

1. US Food and Drug Administration – Avoiding Products Contaminated with Hidden Ingredients

The FDA explains that hidden ingredients may include prescription-drug ingredients, banned substances and other harmful compounds that are not declared on the label.

2. Singapore Health Sciences Authority – Pharmaceutical Analysis

HSA explains that traditional medicines and health supplements may be screened for Western drug adulterants according to their product indications and associated pharmacological effects.

3. International Union of Pure and Applied Chemistry – IUPAC Gold Book — Limit of Detection

IUPAC defines the limit of detection in relation to the smallest measurement that can be detected with reasonable certainty under a particular analytical procedure.

Compliance Notice

Testing is specific to the submitted sample, analytes, analytical methods and detection or reporting limits used.

Laboratory testing does not constitute product approval, certification or endorsement by SGS, HSA, FDA or any other authority. It does not establish clinical effectiveness or guarantee that a product is suitable for every consumer.